Salbutamol (SABA)

This was a common first-line therapy for asthma in the past, but SABA-only treatment is no longer recommended per GINA guidelines, even for mild asthma. While salbutamol provides rapid relief of bronchoconstriction, it does not target the underlying inflammation driving Amy’s symptoms. Reliance on SABAs alone has been shown to increase the risk of exacerbations and it fails to prevent progression of asthma severity over time. SABA use also masks the importance of anti-inflammatory control, which is critical for long-term asthma management.

In Amy’s case, she has symptoms suggestive of mild but persistent inflammation (e.g., nocturnal cough, response to exercise), so an anti-inflammatory component is essential. I encourage you to re-evaluate her needs and confirm which treatment option will address both symptomatic relief and inflammation.